Format

Send to

Choose Destination
Urologe A. 2016 May;55(5):627-31. doi: 10.1007/s00120-015-0021-1.

[Cardiovascular risks of androgen deprivation therapy for prostate cancer].

[Article in German]

Author information

1
Klinik und Hochschulambulanz für Urologie, Charitéplatz 1, 10117, Berlin, Deutschland. kurt.miller@charite.de.

Abstract

Androgen deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer. It has increasingly been used in other stages of the disease as well. Besides well-known side effects caused by the lack of testosterone (impotency, osteoporosis, fatigue, loss of muscle mass), an increase of cardiovascular (CV) morbidity and mortality has recently been discussed in association with ADT. Cardiovascular side effects cannot be sufficiently explained by low testosterone levels. This review gives an overview of the recent literature, interprets the results, and offers clinical consequences.

KEYWORDS:

Androgen deprivation therapy; Cardio vascular events; GnRH antagonists; LHRH agonists; Prostate cancer

PMID:
27003571
DOI:
10.1007/s00120-015-0021-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center